GH Research Investor Relations Material
Latest events
Status Update
GH Research
Q1 2025
7 May, 2025
Q4 2024
27 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from GH Research PLC
Access all reports
GH Research PLC is a clinical-stage biopharmaceutical company focused on developing innovative therapies for psychiatric and neurological disorders. The company's primary area of research is centered on 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT), a psychoactive compound, which is being developed for treating treatment-resistant depression (TRD) and other mental health conditions. GH Research's leading product candidate, GH001, is an inhalable form of mebufotenin, currently in Phase 2b clinical trials for TRD, as well as in earlier trials for Bipolar II disorder and postpartum depression. Additionally, the company is developing GH002, an intravenous formulation, and GH003, an intranasal product. The company is headquartered in Dublin, Ireland, and its shares are listed on the NASDAQ.
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
GHRS
Country
🇺🇸 United States